all report title image

BONE GRAFT SUBSTITUTES MARKET ANALYSIS

Bone Graft Substitutes Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Nov 2024
  • Code : CMI427
  • Formats :
      Excel and PDF
  • Industry : Medical Devices

Market News

Key Developments

  • In March 2019, Bioventus, launched OSTEOAMP SELECT Fiber, allograft substitutes for the bone injury of spine, foot & ankle etc. OSTEOAMP SELECT Fibers are designed in such a way that they retain the necessary growth factors that supports the bone and they also provide channel for cell migration. During the trauma, the bones may break and may form a void. Thus to fuse such bones OSTEOAMP SELECT Fibers can be used.
  • In February 2019, Medtronic launched Grafton, which is a Demineralized Bone Matrix (DBM) and is used for bones of spine and can be used for orthopedic procedures. Grafton, has high osteoinductivity, a crucial factor for bone fusion. This product is used as bone graft extender, substitute, and for filling the voids of the skeletal system.
  • In 2018, Baxter International Inc., received U.S. Food and Drug Administration (U.S. FDA) approval for the Actifuse Flow which is a bone graft substitute, which can be used in orthopedic operative procedures. The product offers faster bone growth in the packaged delivery injection for the insertion of the graft substitute precisely into small bony voids or gaps in the affected bones. 
  • In 2017, NovaBone Products Pvt Ltd., launched two products, NovaBone IRM and the IRM MacroPOR to its collection for bone graft substitutes. The two new products promote osteoblastic and osteogenesis activity wherever they are used as bone graft substitutes.
  • In 2017, Citagenix, Inc., launched PentOS OI Max, a new bone graft substitute for the purpose of oral and maxillofacial surgery, thus, escalating its line of PentOS OI bone grafts. The product consist of an inductive collagen matrix, which can be combined with stem cells and blood components which are derived from patients.
  • In 2017, Anika Therapeutics, Inc., received 510(k) clearance from the S. Food and Drug Administration(U.S. FDA) for its hyaluronic acid bone void filler and is specifically used for correcting the defects of skeletal system. The bone void filler, is composed of a synthetic and bone graft substitute made of biocompatible material, is placed into a void, which solidifies at body temperature, and is then during the healing process, it is resorbed and then replaced by the new bone growth.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.